 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123456 |
- |||||||||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
New P3 trial, Head-to-Head: Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1) (clinicaltrials.gov) - Apr 30, 2015
P3, N=476, Not yet recruiting, Sponsor: ViiV Healthcare
- |||||||||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
New P3 trial, Head-to-Head: Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2) (clinicaltrials.gov) - Apr 21, 2015
P3, N=476, Not yet recruiting, Sponsor: ViiV Healthcare
- ||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
Enrollment open: Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects (clinicaltrials.gov) - Mar 29, 2015
P1, N=60, Recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting
- ||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
New P1 trial: Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects (clinicaltrials.gov) - Feb 27, 2015
P1, N=60, Not yet recruiting, Sponsor: ViiV Healthcare
- || Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
New P2/3 trial, Head-to-Head: Dolutegravir + Rilpivirine Switch Study (DORISS) (clinicaltrials.gov) - Feb 20, 2014
P2/3, N=300, Not yet recruiting, Sponsor: Nantes University Hospital